{
  "id": "5e460f823f54159529000006",
  "type": "factoid",
  "question": "What is the target of galcanezumab?",
  "ideal_answer": "Galcanezumab is a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
    "http://www.ncbi.nlm.nih.gov/pubmed/30187471",
    "http://www.ncbi.nlm.nih.gov/pubmed/31291515",
    "http://www.ncbi.nlm.nih.gov/pubmed/31710104",
    "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
    "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
    "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
    "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
    "http://www.ncbi.nlm.nih.gov/pubmed/31043785",
    "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
    "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
    "http://www.ncbi.nlm.nih.gov/pubmed/31253091",
    "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
    "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
    "http://www.ncbi.nlm.nih.gov/pubmed/31482569",
    "http://www.ncbi.nlm.nih.gov/pubmed/30378008"
  ],
  "snippets": [
    {
      "text": "Importance: Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: Monoclonal antibodies (mAbs) targeting the calcitonin-gene-related peptide (CGRP) pathway have been developed for episodic and chronic migraine prevention, either through binding the CGRP ligand (eptinezumab, fremanezumab, galcanezumab) or the CGRP receptor (erenumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background Safety findings from a Phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (NCT02163993) are reported here.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31291515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance\n\nGalcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may be effective in migraine prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (CGRP), is effective for migraine prevention with a favorable safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31253091",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may be effective in migraine prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Failures in development of small molecule CGRP receptor antagonists and increasing knowledge and use of monoclonal antibodies ( mAbs ) in medicine led to the breakthrough development of large molecule anti-CGRP mAbs: eptinezumab , erenumab , fremanezumab , and galcanezumab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30187471",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab , an anti-CGRP antibody",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Monoclonal antibodies ( mAbs ) targeting the calcitonin-gene-related peptide ( CGRP ) pathway have been developed for episodic and chronic migraine prevention , either through binding the CGRP ligand ( eptinezumab , fremanezumab , galcanezumab ) or the CGRP receptor ( erenumab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31291515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide and is indicated for preventive treatment of migraine.DESIGN/",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31710104",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) and has demonstrated efficacy in reducing migraine headache days (MHD) in patients with episodic and chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab is one of the antibodies developed and studied to prevent migraine by targeting CGRP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31043785",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab-gnlm (Emgality\u2122; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30378008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide (CGRP), is effective for migraine prevention with a favorable safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31253091",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31291515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab is a humanized immunoglobulin G (IgG) monoclonal antibody (mAb) indicated for the prevention of migraine that binds to calcitonin gene-related peptide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31482569",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917684",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "calcitonin gene-related peptide"
}